Publications in collaboration with researchers from Icahn School of Medicine at Mount Sinai (8)

2022

  1. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2021

  1. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

    Journal of Clinical Pharmacology, Vol. 61, Núm. 5, pp. 614-627

  2. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

    Haematologica, Vol. 106, Núm. 6, pp. 1725-1732

  3. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

    The Lancet, Vol. 398, Núm. 10301, pp. 665-674

2020

  1. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

2019

  1. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

    Blood, Vol. 134, Núm. 8, pp. 668-677

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2011

  1. Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3

    Blood